76 studies found for:    myeloma AND (women OR woman OR female)
Show Display Options
Rank Status Study
21 Recruiting S1304, Testing Two Doses of Carfilzomib With Dexamethasone for Relapsed or Refractory Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: carfilzomib
22 Recruiting A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Sotatercept;   Drug: Placebo
23 Active, not recruiting S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Conditions: Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma;   Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
24 Recruiting ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: ACE-011;   Drug: Lenalidomide;   Drug: Dexamethasone
25 Active, not recruiting Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Drug: bortezomib;   Other: laboratory biomarker analysis
26 Unknown  Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study
Condition: Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation
Intervention: Drug: Bortezomib
27 Active, not recruiting
Has Results
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: filgrastim;   Biological: sargramostim;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide;   Procedure: peripheral blood stem cell transplantation
28 Terminated Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.
Conditions: Vertebral Fracture;   Multiple Myeloma;   Osteolytic Metastases
Intervention: Device: balloon kyphoplasty
29 Completed
Has Results
American Ginseng in Treating Patients With Fatigue Caused by Cancer
Conditions: Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: American ginseng;   Other: placebo
30 Completed ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Conditions: Bone Metastases;   Multiple Myeloma
Interventions: Device: ExAblate 2000;   Device: Sham
31 Completed A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Conditions: Lymphoma, Mantle-cell;   Leukemia, Lymphocytic, Chronic, B-Cell;   Leukemia, Hairy Cell;   Waldenstrom Macroglobulinemia;   Multiple Myeloma
Intervention: Drug: ON01910 Na
32 Recruiting Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
33 Recruiting Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
Conditions: Relapsed Multiple Myeloma;   End-stage Renal Disease
Intervention: Drug: Carfilzomib
34 Recruiting Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Conditions: Acute Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Intervention: Genetic: cytogenetic analysis
35 Recruiting Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
Condition: MULTIPLE MYELOMA (MM)
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Lenalidomide;   Drug: Dexamethasone
36 Recruiting A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
Condition: Multiple Myeloma
Intervention:
37 Active, not recruiting Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Conditions: Ovarian Cancer;   Renal Cancer;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Solid Tumors;   Multiple Myeloma;   Lymphoma
Interventions: Drug: Carfilzomib 30 min IV infusion;   Drug: Carfilzomib bolus administration up to 10 min;   Drug: Carfizomib 30 min infusion plus 40 mg/week dexamethasone
38 Active, not recruiting Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
39 Active, not recruiting Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: bortezomib
40 Recruiting Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years